2022
Vonoprazan Versus Lansoprazole for Healing and Maintenance of Healing of Erosive Esophagitis: A Randomized Trial
Laine L, DeVault K, Katz P, Mitev S, Lowe J, Hunt B, Spechler S. Vonoprazan Versus Lansoprazole for Healing and Maintenance of Healing of Erosive Esophagitis: A Randomized Trial. Gastroenterology 2022, 164: 61-71. PMID: 36228734, DOI: 10.1053/j.gastro.2022.09.041.Peer-Reviewed Original ResearchMeSH KeywordsAdultEsophagitisHumansLansoprazolePeptic UlcerProton Pump InhibitorsPyrrolesSulfonamidesTreatment OutcomeConceptsMaintenance of healingProton pump inhibitorsErosive esophagitisSecondary analysisD esophagitisPrimary analysisEnd pointPotassium-competitive acid blocker vonoprazanHeartburn-free daysSevere erosive esophagitisMainstay of treatmentPrimary end pointSecondary end pointsPotent acid inhibitionPPI lansoprazolePump inhibitorsEsophagitisNoninferiority comparisonVonoprazanWeek 2Healing phaseAbstractTextPatientsLansoprazoleSuperiority analysis
2014
Causes of Bleeding and Outcomes in Patients Hospitalized With Upper Gastrointestinal Bleeding
Kim JJ, Sheibani S, Park S, Buxbaum J, Laine L. Causes of Bleeding and Outcomes in Patients Hospitalized With Upper Gastrointestinal Bleeding. Journal Of Clinical Gastroenterology 2014, 48: 113-118. PMID: 23685847, DOI: 10.1097/mcg.0b013e318297fb40.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overEndoscopy, GastrointestinalEsophageal and Gastric VaricesEsophagitisFemaleGastrointestinal HemorrhageHematemesisHospital MortalityHospitalizationHumansLength of StayMaleMedicaidMedicareMelenaMiddle AgedPeptic UlcerPeptic Ulcer HemorrhageRetreatmentRetrospective StudiesUnited StatesConceptsUpper gastrointestinal bleedingGastrointestinal bleedingCommon causeOutcomes of UGIBVariceal upper gastrointestinal bleedingNonvariceal upper gastrointestinal bleedingCause of bleedingRisk of deathLower socioeconomic patientsUrban US hospitalsErosive esophagitisInpatient mortalityRepeat endoscopyUpper endoscopyConsecutive patientsClinical outcomesPeptic ulcerMean ageMedical CenterUrban hospitalPatientsUS hospitalsMultivariate analysisHematemesisEndoscopy
2010
Randomised clinical trial: a novel rabeprazole extended release 50 mg formulation vs. esomeprazole 40 mg in healing of moderate‐to‐severe erosive oesophagitis – the results of two double‐blind studies
Laine L, Katz PO, Johnson DA, Ibegbu I, Goldstein MJ, Chou C, Rossiter G, Lu Y. Randomised clinical trial: a novel rabeprazole extended release 50 mg formulation vs. esomeprazole 40 mg in healing of moderate‐to‐severe erosive oesophagitis – the results of two double‐blind studies. Alimentary Pharmacology & Therapeutics 2010, 33: 203-212. PMID: 21114792, DOI: 10.1111/j.1365-2036.2010.04516.x.Peer-Reviewed Original ResearchConceptsHeartburn resolutionErosive oesophagitisExtended releaseLA grade CSevere erosive oesophagitisDouble-blind trialDouble-blind studyPossibility of benefitCurrent PPIsD oesophagitisSevere oesophagitisGERD patientsSecondary endpointsPrimary endpointSymptomatic resolutionAcid suppressionSubgroup analysisDrug exposureClinical trialsOesophagitisGrade DGrade CFurther evaluationEsomeprazoleAcid inhibition
2002
Effect of Helicobacter pylori eradication on development of erosive esophagitis and gastroesophageal reflux disease symptoms: a post hoc analysis of eight double blind prospective studies
Sugg J, Laine L. Effect of Helicobacter pylori eradication on development of erosive esophagitis and gastroesophageal reflux disease symptoms: a post hoc analysis of eight double blind prospective studies. The American Journal Of Gastroenterology 2002, 97: 2992. PMID: 12492181, DOI: 10.1111/j.1572-0241.2002.07116.x.Peer-Reviewed Original ResearchMeSH KeywordsEsophagitisGastroesophageal RefluxHelicobacter InfectionsHelicobacter pyloriHumansSeverity of Illness IndexConceptsPersistent H. pyloriErosive esophagitisGERD symptomsH. pyloriSymptomatic GERDPersistent infectionDouble-blind prospective studyDouble-blind prospective trialGastroesophageal reflux disease symptomsCompletion of therapyDuodenal ulcer diseaseGastroesophageal reflux diseaseHelicobacter pylori eradicationHelicobacter pylori therapyWorsening of symptomsEnd of therapyRapid urease testBlind prospective studyPylori eradicationPylori therapyReflux diseaseRegurgitation scoreProspective trialDuodenal ulcerUlcer disease
1992
Fluconazole compared with ketoconazole for the treatment of Candida esophagitis in AIDS. A randomized trial.
Laine L, Dretler RH, Conteas CN, Tuazon C, Koster FM, Sattler F, Squires K, Islam MZ. Fluconazole compared with ketoconazole for the treatment of Candida esophagitis in AIDS. A randomized trial. Annals Of Internal Medicine 1992, 117: 655-60. PMID: 1308663, DOI: 10.7326/0003-4819-117-8-655.Peer-Reviewed Original ResearchConceptsCandida esophagitisCounty hospital settingFluconazole-treated patientsDouble-blind trialResolution of symptomsOral antifungal agentsEnd of therapyEndoscopic responseRetrosternal painStudy medicationClinical cureEsophageal symptomsSymptomatic improvementTreat analysisImmunodeficiency syndromeEndoscopic cureAntifungal therapyEsophageal brushingsHospital settingPatientsSide effectsWeek 1U.S. CentersEsophagitisTherapy
1991
The causes of esophageal symptoms in human immunodeficiency virus infection. A prospective study of 110 patients.
Bonacini M, Young T, Laine L. The causes of esophageal symptoms in human immunodeficiency virus infection. A prospective study of 110 patients. JAMA Internal Medicine 1991, 151: 1567-72. PMID: 1651690, DOI: 10.1001/archinte.151.8.1567.Peer-Reviewed Original ResearchConceptsHuman immunodeficiency virus (HIV) infectionImmunodeficiency virus infectionBlind brushingHerpes simplex virusViral cultureHistologic examinationVirus infectionCandida esophagitisEsophageal symptomsSimplex virusViral infectionProspective clinical case studyUrban county hospitalPositive predictive valueDiagnosis of esophagitisEsophageal infectionsInfectious esophagitisViral esophagitisConsecutive patientsOral thrushOrogastric tubeEsophageal biopsiesProspective studyVirologic testingBiopsy specimens